List view / Grid view
License agreement set to advance mRNA-3927, a potential disease modifying…
License agreement set to advance mRNA-3927, a potential disease modifying therapy for the rare metabolic disorder propionic acidemia.
24-month FDA post marketing commitment completed...
13 February 2014 | By Teva
24-month FDA post marketing commitment completed...
TEVA announced that the European Commission has granted marketing authorization…
8 August 2013 | By Teva Pharmaceutical Industries Ltd
TEVA announced that the European Commission has granted marketing authorization for Lonquex® (lipegfilgrastim)...
Teva’s Lonquex® (XM22 lipegfilgrastim) recommended for approval in the EU…
3 June 2013 | By Teva Pharmaceutical Industries Ltd
Teva’s Lonquex® (XM22 lipegfilgrastim) recommended for approval in the EU for the reduction of CIN...
